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Summary: The aims of our study were to evaluate the plasma Carboxypeptidase N activity in normal subjects and
in patients with acute myocardial infarction and to delineate its relationship with creatine kinase-MB isoforms in
monitoring of acute myocardial infarction, Carboxypeptidase N being the major determinant of creatine kinase
isoform conversion in plasma. The study was carried out in 34 healthy subjects and 19 patients with acute myocar-
dial infarction diagnosed according to the World Health Organization (WHO) criteria in which the blood samples
were collected immediately upon admission to the coronary care unit (median time 3.5 hours), every 4 to 6 hours
for 24 hours, and every 12 hours until the third day post admission. Carboxypeptidase N activity, total creatine
kinase, creatine kinase-MB mass concentration and creatine kinase-MB isoforms were determined in each sample
from acute myocardial infarction patients, whereas only Carboxypeptidase N and total creatine kinase activities
were assayed in samples from healthy subjects. The results showed a high variability in Carboxypeptidase N values
among healthy subjects (median = 220 U/l; interquartile range = 190—247 U/l) and in the first available samples
from acute myocardial infarction patients (median = 213 U/l; interquartile range = 197—234 U/l) without signifi-
cant differences between groups and without a correlation between Carboxypeptidase N and creatine kinase activities
either in healthy subjects or in acute myocardial infarction patients; in the latter group, however, a significant
correlation (p < 0.01) with creatine kinase-MB calculated on all samples, was observed. In acute myocardial infarc-
tion patients Carboxypeptidase N showed time-related variations, reaching the highest levels about 48 h after onset
of chest pain. A statistically significant difference in Carboxypeptidase N values (p = 0.0001) was found before
and after creatine kinase-MB peak values as well as before and after MB2/MB! normalization. Worthy of note is
the finding that in two acute myocardial infarction patients presenting MB2/MBj ratios lower than the cutoff value
(1.5) throughout the period of observation, the baseline values for Carboxypeptidase N were higher than in other
patients studied. Our results suggest that the increase of Carboxypeptidase N activity after infarction could be
induced by an increase in endogenous substrate concentrations, in particular creatine kinase-MB released from
damaged myocardium. Furthermore, high baseline levels of Carboxypeptidase N will reduce the diagnosis efficiency
of creatine kinase-MB isoforms in the diagnosis of acute myocardial infarction.
Introduction myocardial infarction as well as for the assessment of
The creatine kinase-MB isoforms and, in particular, coronai^ rePerfi*ion after thrombolytic therapy (1-4).
the MB2 (tissue isoform containing C-terminal lysine) Moreover> now that a real-time, fully-automated method
to MB! (circulating des-lysine isoform) ratio is a sensi- is available for their ™asurement, this assay is also an
tive and specific marker for the early diagnosis of acute mterestmS too1 for the early diagnosis of acute Wocar-
dial infarction in emergency (5, 6). Previous studies
(1—9) indicated that the tissue creatine kinase-MB2 iso-
1) Enzymes: form released from the damaged myocardium is con-
Carboxypeptidase N (arginine Carboxypeptidase, EC 3.4.17.3); verted in the blood to creatine kinase-MB! by carboxy-
Creatine kinase (ATP : creatine N-phosphotransferase, EC 2.7.3.2).
 oeotidase χ,κ an enzvme synthesized in the liver and2) Remark of the Managing Editor: peptmase IN ), an enzyme syntnesizea in me nver ana
The absorption coefficient at 336 nm is given by 1. c. (15) with secreted as a Mr = 280 000 tetramer and which is known
Δε = -1300 Μ'1 cnr1, corresponding to 130m2 x mor1. In to be an important inactivator of peptide hormones such
I.e. (13) "an absorption coefficient of 0.13 L · nmol ' · min '"is , , , . . , ι ι ^ · A 1^ .1 u ^
given. This was repeated by Skidgel RA, Erdos EG. Carboxypepti- as bradykimn and anaphylatoxms. Although the enzyme
dase N (arginine Carboxypeptidase) peptidyl-Z,-arginine hydrolase, appears to be present in all humans, its levels in plasma
EC 3.4.17.3. In: Bergmeyer HU, editor. Methods of enzymatic
 vary considerably among subjects. In normal subjects,
analysis. 3rd English ed., vol. V. Weinheim: Verlag Chemie, . ., , . , , . . . .
1988:60-72. In the latter two publications it should read: 0.131 m fact' UP to a threefold variation in enzyme activity
x mmor1 x mm~', also corresponding to 130m2 χ mol"1. has been observed; during pregnancy and during the
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course of certain types of cancer, elevated enzyme con-
centrations have been reported while low concentrations
have been observed in patients with cirrhosis of the liver
(10, 11). The reported variability in Carboxypeptidase N
activities may therefore be important in the use of the
creatine kinase-MB isoform ratio for the diagnosis of
myocardial infarction: in fact, the sensitivity and the
diagnostic accuracy of isoform analysis for the detection
of infarction will likely depend, in part, on the rate of
conversion of isoforms in plasma (12). However, despite
some evidence correlating variations of Carboxypepti-
dase N and creatine kinase-MM in acute myocardial in-
farction (13), no data exist on the relationship between
plasma Carboxypeptidase N activity and creatine kinase-
MB isoforms in acute myocardial infarction.
The aim of this study was to delineate the relationship
between creatine kinase-MB isoforms and carboxypepti-
dase N activity in patients with acute myocardial infarc-
tion.
buffer (0.05 mol/1 HEPES, pH 7.75, 0.25 mol/1 NaCl) containing
0.5 mmol/1 of substrate, previously equilibrated at 37 °C. Absor-
bance was measured at 336 nm over a 6 minute period; the enzyme
activities, calculated using a conventional method with a molar
absorption coefficient2) of 130 m2 X mol"1 (13), were expressed
as U/l (l U = amount of enzyme hydrolyzing 1 μιηοΐ of furylacry-
loyl-alanyl-lysine per minute).
The within-day coefficient of variation (n = 11) was 4.8% at a
mean value of 217 U/l and 3.6% at 251 U/l. In the same sera,
between-day coefficients of variation of 7.5% and 6.3% respec-
tively were obtained.
Total creatine kinase catalytic activity concentration
The catalytic concentration of creatine kinase was determined at
37 °C (Bracco, Milano, Italy) according to the method recom-
mended by the IFCC (16). The upper reference limits were > 160
U/l for females and > 190 U/l for males.
Creatine kinase-MB mass concentration
The mass concentration of creatine kinase-MB was measured using
a commercially available fluorometric enzyme immunoassay (Stra-
tus CK-MB; Baxter Dade, Milano, Italy) with a sensitivity of 0.4
μ§/1. The upper reference limit was 5 μ^Ι.
Materials and Methods
Subjects and blood collection
The study was carried out on 34 healthy subjects (14 males and 20
females, aged 23 to 55 years) from the laboratory staff and 19
patients (12 men and 7 women, aged 46 to 74 years) with acute
myocardial infarction diagnosed according to WHO criteria (char-
acteristic chest pain, unequivocal ECG changes and serial increases
in creatine kinase and creatine kinase-MB mass concentration with
peak values twice the upper limit of the reference interval); 14 had
Q-wave and 5 non-Q-wave indicated infarctions. The patients were
admitted to the coronary care unit within 9 hours after the onset of
symptoms (range 0.5—9 h; median 3.5 h); 12 underwent thrombo-
lytic treatment while 7 were not treated depending on clinical cir-
cumstances; 10 were classified as reperfused on the basis of their
clinical pictures (symptoms resolved rapidly, ST-segment changes
improved, presence of reperfusion arrhythmias) (14). Blood sam-
ples were collected from patients immediately upon admission to
the coronary care unit and every 4 to 6 hours thereafter for 24
hours and then every 12 hours until the third day of hospitalization.
All patients gave their informed consent for extra blood samples
to be drawn. Carboxypeptidase Ν activity, total creatine kinase,
creatine kinase-MB mass concentration and creatine kinase-MB
isoforms were determined in each sample from acute myocardial
infarction patients, whereas only Carboxypeptidase Ν and total cre-
atine kinase activities were assayed in samples from the healthy
subjects.
Venous blood samples for the measurement of creatine kinase, cre-
atine kinase-MB mass and Carboxypeptidase Ν were drawn in lith-
ium heparinate-containing tubes, centrifuged at 2000 g for 15 min-
utes and analyzed immediately. Samples for creatine kinase iso-
form determination were collected in tubes containing ethylene
glycol bis ( -aminoethyl ether)-N,N,N',N'tetracetic acid (EGTA,
final concentration 30 mmol/1) and 2-mercaptoethanol (final con-
centration 10 mmol/1) to inhibit Carboxypeptidase N-mediated iso-
form conversion after blood collection, and the EGTA-plasma was
stored at -20 °C until analysis (1).
Methods
Carboxypeptidase N activity
Spectrophotometric assay at 37 °C using furylacryloyl-alanyl-ly-
sine as the substrate (Sigma Diagnostic, Milano, Italy) according
to Plummer & Kimmel (15) was used to measure Carboxypeptidase
N activity, 40 μΐ of sample being added to 3 ml of the reaction
Creatine kinase-MB isoforms
Using high-voltage electrophoresis on agarose gels with the auto-
mated REP/EDC system (Helena Laboratories, Milano, Italy) cre-
atine kinase-MB isoforms were separated, and then detected by
fluorescence densitometry. This procedure also enables the separa-
tion of creatine kinase-MM isoforms, but only the more specific
cardiac creatine kinase-MB isoforms were considered in our study,
two creatine kinase-MB isoforms being separated with this pro-
cedure: according to their electrophoretic mobilities, isoform cre-
atine kinase-MB2 is the most cathodic band while creatine kinase-
MB! is the fastest moving, most anodic band in the creatine ki-
nase series.
The within-run and between-run precision (CVs) calculated in a
sample with MB2/MBj ratio of 0.93 and MB2 activity of 5.8 U/l
were 9.1% and 11.6% respectively. The minimum MB activity for
isoform analysis using this procedure was 4 ± 1 U/l. The upper
reference limit for the MB2/MBi ratio was 1.5 (5).
Statistics and calculation
Medians and percentiles were calculated to described continuous
variables. Two-way unpaired t-tests were used for between-group
comparison of the results, while one-way paired t-tests were used
to compare the results from acute myocardial infarction patients: p
values < 0.05 were considered to indicate statistical significance.
Results
The Carboxypeptidase N activities in plasma of normal
subjects and in the first blood sample of patients with
myocardial infarction collected 3.5 h (median) after the
onset of chest pain show a high variability over a two-
fold range among subjects, without a significant differ-
ence between controls (median = 220 U/l; interquartile
range = 190—247 U/l) and acute myocardial infarction
patients (median = 213 U/l; interquartile range = 197—
234 U/l).
The pattern of Carboxypeptidase N values in patients
with myocardial infarction (fig. 1) shows time-related
variations, the highest levels (ranging from 10 to 72%
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Fig. 1 Time-related variations of Carboxypeptidase Ν and total
creatine kinase in patients with acute myocardial infarction (mean
values ± SE).
to initial values) being reached about 48 hours after the
onset of chest pain, and maintained for more than 60
hours. The increased values in Carboxypeptidase Ν con-
centrations following infarction and the maximum level
therefore occurred in each patient later also in respect to
total creatine kinase, the last marker of acute myocardial
infarction to be considered in our study. Furthermore, no
correlation was found between Carboxypeptidase Ν and
total creatine kinase values either in healthy subjects
(n = 34; r = 0.051, p = 0.774) or in all samples of acute
myocardial infarction patients (n = 171; r = 0.346,
p = 0.061), while in the latter group a significant corre-
lation between Carboxypeptidase N and creatine kinase-
MB concentrations (r = 0.479; p < 0.01) was obtained.
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Fig. 2 Distribution of Carboxypeptidase N values from patients
with acute myocardial infarction in relation to creatine kinase-MB
peak concentrations.
Figure 2 shows the relationship between carboxypepti-
dase N values and creatine kinase MB mass concentra-
tion (median time to peak concentration 15 h; interquar-
tile range 10—26 h) in patients studied. The reported re-
sults show that the values of Carboxypeptidase N ob-
tained from each patient in the sample collected before
creatine kinase-MB peak concentrations (median = 201
U/l, interquartile range: 184—223 U/l), were signifi-
cantly lower (p = 0.0001) than those obtained from the
samples collected after creatine kinase-MB peak values
(median = 227 U/l, interquartile range: 211-242 U/l).
In the same patients the relationship between Carboxy-
peptidase N and the MB2/MB! ratio shows, as expected,
a statistically significant difference (p = 0.0001) be-
tween Carboxypeptidase N values before (median =184
U/l, interquartile range: 171-201) and after (median
= 209 U/l, interquartile range: 203-243 U/l) MB2/MBl
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Fig. 3 Distribution of Carboxypeptidase N values from patients
with acute myocardial infarction in relation to the creatine kinase-
MB isoform ratio.
normalization (fig. 3). However, in two out of the 19
acute myocardial infarction patients monitored in our
study, the creatine kinase-MB isoform ratio was lower
than the cutoff value (x ± SD: 0.39 ±0.13 and 0.51
±0.12 respectively) throughout the period of observa-
tion. In these two patients the first blood samples were
obtained shortly after the onset of chest pain (2.5 and
2.0 hours respectively), with creatine kinase-MB con-
centrations ranging from 6.3 to 246 μg/l and from 7.8 to
351 μg/l (baseline and peak values respectively). Worthy
of note is the finding that in these patients the baseline
Carboxypeptidase N values (222 U/l and 228 U/l respec-
tively) were higher compared to those from patients
(n = 8) with similar hospital admission time (2—3.5 h)
in which the median baseline value was 189 U/l (inter-
quartile range: 174—206 U/l). These observations sug-
gest that the baseline values of Carboxypeptidase N aciti-
vity in acute myocardial infarction patients were respon-
sible for early conversion of tissue MB2 isoform into
plasma MB! isoform allowing an early shift of the MB2/
ratio.
Discussion
Analysis of isoforms of creatine kinase-MB in plasma
was recently shown to enable the detection of acute
myocardial infarction and of coronary recanalization
very early after their onset, before a significant elevation
in total creatine kinase activity and, in some cases, ere-
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atine kinase-MB (1—6). The sensitivity of isoform
analysis results from the early release from the damaged
myocardium of the tissue isoenzyme of MB (MB2),
which is converted in plasma into an additional subform
(MB}) with a similar specific activity but different iso-
electric point (isoforms). Thus, the release in plasma of a
modest amount of creatine kinase-MB2 after myocardial
infarction causes a prompt and marked increase in the
MB2 to MBi ratio (17, 18, 20-22).
Several studies have shown that carboxypeptidase N is
the main factor accounting for isoform conversion in
human plasma under physiological conditions (7—11)
and after myocardial infarction, elucidating in particular
the relation between carboxypeptidase N activity in
plasma and observed rates of creatine kinase-MM iso-
form conversion (13).
On the basis of these suggestions, the aim of our study
was to ascertain the variations in plasma carboxypepti-
dase N activity in normal subjects and in patients under-
going acute myocardial infarction and to delineate its
relationship with creatine kinase-MB isoforms. The car-
boxypeptidase N levels were assessed using a sensitive
and specific method, showing good analytical perfor-
mance, as previously demonstrated (15).
Time-related variations of carboxypeptidase N activity
in patients with acute myocardial infarction were found
with the highest level being reached about 48 hours after
the onset of pain. In none of the subjects studied was a
correlation observed between carboxypeptidase N and
total creatine kinase values. However, a significant cor-
relation between carboxypeptidase N and creatine ki-
nase-MB concentrations has been found in patients with
myocardial infarction, carboxypeptidase N values being
significantly different in relation to creatine kinase-MB
peak concentrations.
These results suggest that the increase in carboxypepti-
dase N after infarction might be induced by the increase
in endogenous substrate concentrations, in particular
creatine kinase-MB, released from the damaged myocar-
dium and emphasize the need of further studies for bet-
ter understanding the behaviour of this enzymatic activ-
ity.
Moreover, our findings underline the relevance of car-
boxypeptidase N determination for the accurate diagno-
sis of acute myocardial infarction using the assay of cre-
atine kinase-MB isoforms. In fact, two evaluated pa-
tients, who during monitoring had MB2 to MB ι ratios,
lower than the cutoff value, had high baseline carboxy-
peptidase levels yielding false negative results. This evi-
dence, in conjunction with the already described influ-
ence of low carboxypeptidase Ν levels in normal sub-
jects leading to false positive results for the MM isoform
ratio (13), emphasizes the need for caution in evaluating
the creatine kinase-MB isoform results in acute myocar-
dial infarction.
Conclusion
The determination of creatine kinase-MB isoforms in
plasma provides considerable advantages for the early,
non-invasive detection of acute myocardial infarction as
well as for the evaluation of coronary recanalization.
Nevertheless, findings made by us and by other authors
(12, 13) indicate that the biological variations in carb-
oxypeptidase N activity may be of importance in the
clinical use of the creatine kinase-MB isoform ratio.
Thus, the determination of carboxypeptidase N concen-
trations using a rapid and analytically accurate pro-
cedure may increase the specificity and the sensitivity of
this test in the diagnosis of acute myocardial infarction.
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